General Information of Drug (ID: DMQOF53)

Drug Name
PMID29334795-Compound-66 Drug Info
Cross-matching ID
PubChem CID
118063527
TTD Drug ID
DMQOF53

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Histamine H3 receptor (H3R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pitolisant DM8RFNJ Excessive daytime sleepiness MG42 Approved [2]
SUVN-G3031 DM3BO8G Cognitive impairment 6D71 Phase 3 [3]
JNJ-17216498 DM1GRCU Narcolepsy 7A20 Phase 2 [4]
GSK239512 DMBJMZC Alzheimer disease 8A20 Phase 2 [5]
JNJ-39220675 DM0WY3H Alcohol dependence 6C40.2 Phase 2 [6]
AZD-5213 DMOZ04X Alzheimer disease 8A20 Phase 2 [7]
Bavisant DM6CVZ5 Attention deficit hyperactivity disorder 6A05.Z Phase 2 [8]
ABT-288 DM7X54F Alzheimer disease 8A20 Phase 2 [9]
SAR-110894 DMCLEXM Alzheimer disease 8A20 Phase 2 [7]
ABT-652 DMLEO2Z Diabetic neuropathy 8C0Z Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D2 receptor (D2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [11]
Haloperidol DM96SE0 Delirium Approved [12]
Perphenazine DMA4MRX Schizophrenia 6A20 Approved [13]
Perazine DM2AOTZ Psychotic disorder 6A20-6A25 Approved [14]
Domperidone DMBDPY0 Gastrointestinal disease DE2Z Approved [15]
Levodopa DMN3E57 Parkinson disease 8A00.0 Approved [16]
Quetiapine DM1N62C Anorexia nervosa cachexia 6B80 Approved [17]
Pimozide DMW83TP Schizophrenia 6A20 Approved [18]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [19]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Ligand [1]
Histamine H3 receptor (H3R) TT9JNIC HRH3_HUMAN Inhibitor [1]

References

1 Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol. 2004 Nov;143(5):649-61.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6 JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl). 2011 Apr;214(4):829-41.
7 SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14.
8 Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26(5):421-34.
9 A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.J Alzheimers Dis.2014;42(3):959-71.
10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032225)
11 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
12 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
13 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
14 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
15 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
17 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
18 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
19 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
20 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.